Effects of tumor mutation burden on the antigen presentation pathway

Published in bioRxiv

April 14, 2021

Abstract: Tumor mutation burden (TMB) is used to select patients to receive immune checkpoint inhibitors (ICIs) but has mixed predictive capabilities. We hypothesized that inactivation of antigen presenting genes (APGs) that result from increased TMBs would result in inherent resistance to ICIs. We observed that somatic mutations in APGs were associated with increasing TMBs across 9,418 tumors of 33 different types. In adenocarcinomas of the lung, ITGAX and CD1B were some of the most commonly mutated APGs. In 62 patients with non-small cell lung cancers treated with a PD-1 inhibitor in second or later lines of therapy, there was an association of increased TMB with mutations in APGs; however, mutations in one or more APGs were associated with improved progression-free survival. Contrary to our hypothesis, mutations in APGs were associated with improved progression-free survival with nivolumab, possibly due to the involvement of single alleles rather than complete loss.



Enrique M. Garcia-Rivera, Jiho Park, Aakash Desai, Romain Boidot, Sandy Chevrier, Caroline Truntzer, Francois Ghiringhelli, Mitesh Borad, Aaron S. Mansfield 

nference, Cambridge, Massachusetts, USA

Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

Unit of Molecular Biology, Georges-Francois LeClerc Cancer Center, Dijon, France

Genetic and Immunology Medical Institute, Dijon, France

University of Burgundy Franche-Comte, France

Division of Hematology and Oncology, Mayo Clinic Scottsdale, AZ, USA

Co-Directors of Precision Cancer Therapeutics within the Center of Individualized Medicine, Mayo Clinic, USA

Correspondence: Aaron Mansfield (mansfield.aaron@mayo.edu)





The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.